Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bivona

Showing results (21-30 of 514) with videos related to

Pageof 52
Sort By:
Molecular & Cellular Oncology|June 17, 2016
The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitorsLuping Lin, Trever G Bivona
Cell Cycle (Georgetown, Tex.)|December 15, 2015
RAS-MAPK in ALK targeted therapy resistanceGorjan Hrustanovic, Trever G Bivona
Cancer Cell|June 25, 2021
Stepwise evolution of therapy resistance in AMLPhilippe Gui, Trever G Bivona
Molecular & Cellular Oncology|June 17, 2016
RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancerGorjan Hrustanovic, Trever G Bivona
Small Gtpases|February 23, 2016
RAS signaling in ALK fusion lung cancerGorjan Hrustanovic, Trever G Bivona
The Journal of Clinical Investigation|February 15, 2022
Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancerTadashi Manabe, Trever G Bivona
Caring : National Association for Home Care Magazine|November 4, 1992
The nutrition screening initiativeM F Tonore, B Bivona
Oncogene|February 24, 2015
Adaptive stress signaling in targeted cancer therapy resistanceE Pazarentzos, T G Bivona
Trends in Cancer|March 23, 2019
Polytherapy and Targeted Cancer Drug ResistanceNilanjana Chatterjee, Trever G Bivona
Trends in Cancer|December 7, 2021
Evolution of metastasis: new tools and insightsPhilippe Gui, Trever G Bivona
Pageof 52

Showing results (21-30 of 514) with videos related to

Sort By:
Pageof 52
Molecular & Cellular Oncology|June 17, 2016
The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitorsLuping Lin, Trever G Bivona
Cell Cycle (Georgetown, Tex.)|December 15, 2015
RAS-MAPK in ALK targeted therapy resistanceGorjan Hrustanovic, Trever G Bivona
Cancer Cell|June 25, 2021
Stepwise evolution of therapy resistance in AMLPhilippe Gui, Trever G Bivona
Molecular & Cellular Oncology|June 17, 2016
RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancerGorjan Hrustanovic, Trever G Bivona
Small Gtpases|February 23, 2016
RAS signaling in ALK fusion lung cancerGorjan Hrustanovic, Trever G Bivona
The Journal of Clinical Investigation|February 15, 2022
Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancerTadashi Manabe, Trever G Bivona
Caring : National Association for Home Care Magazine|November 4, 1992
The nutrition screening initiativeM F Tonore, B Bivona
Oncogene|February 24, 2015
Adaptive stress signaling in targeted cancer therapy resistanceE Pazarentzos, T G Bivona
Trends in Cancer|March 23, 2019
Polytherapy and Targeted Cancer Drug ResistanceNilanjana Chatterjee, Trever G Bivona
Trends in Cancer|December 7, 2021
Evolution of metastasis: new tools and insightsPhilippe Gui, Trever G Bivona
Pageof 52